Logo image of BIVI

BIOVIE INC (BIVI) Stock Overview

NASDAQ:BIVI - US09074F4054 - Common Stock

1.6 USD
+0.08 (+5.26%)
Last: 8/22/2025, 8:00:02 PM
1.6554 USD
+0.06 (+3.46%)
After Hours: 8/22/2025, 8:00:02 PM

BIVI Key Statistics, Chart & Performance

Key Statistics
52 Week High75
52 Week Low1.46
Market Cap12.58M
Shares7.86M
Float7.61M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-21.14
PEN/A
Fwd PEN/A
Earnings (Next)09-29 2025-09-29/amc
IPO01-14 2014-01-14
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


BIVI short term performance overview.The bars show the price performance of BIVI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60 -80

BIVI long term performance overview.The bars show the price performance of BIVI in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of BIVI is 1.6 USD. In the past month the price decreased by -78.61%. In the past year, price decreased by -95.05%.

BIOVIE INC / BIVI Daily stock chart

BIVI Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.89 372.00B
AMGN AMGEN INC 13.47 157.94B
GILD GILEAD SCIENCES INC 14.83 142.77B
VRTX VERTEX PHARMACEUTICALS INC 23.32 101.30B
REGN REGENERON PHARMACEUTICALS 12.92 63.65B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.25B
ARGX ARGENX SE - ADR 71.2 40.39B
ONC BEONE MEDICINES LTD-ADR 5.78 37.29B
INSM INSMED INC N/A 27.88B
BNTX BIONTECH SE-ADR N/A 26.66B
NTRA NATERA INC N/A 22.61B
BIIB BIOGEN INC 8.7 20.42B

About BIVI

Company Profile

BIVI logo image BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders and liver disease. The company is headquartered in Carson City, Nevada and currently employs 14 full-time employees. The company went IPO on 2014-01-14. In neurodegenerative disease, the Company’s drug candidate bezisterim (NE3107) inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor, Nuclear factor- kB, and the associated neuroinflammation and insulin resistance but not extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) homeostatic functions (insulin signaling and neuron growth and survival). Both inflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is in the phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites.

Company Info

BIOVIE INC

680 W Nye Lane, Suite 201

Carson City NEVADA 90404 US

CEO: Cuong Do

Employees: 14

BIVI Company Website

BIVI Investor Relations

Phone: 17758883162

BIOVIE INC / BIVI FAQ

What is the stock price of BIOVIE INC today?

The current stock price of BIVI is 1.6 USD. The price increased by 5.26% in the last trading session.


What is the ticker symbol for BIOVIE INC stock?

The exchange symbol of BIOVIE INC is BIVI and it is listed on the Nasdaq exchange.


On which exchange is BIVI stock listed?

BIVI stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for BIOVIE INC stock?

7 analysts have analysed BIVI and the average price target is 56.1 USD. This implies a price increase of 3406.25% is expected in the next year compared to the current price of 1.6. Check the BIOVIE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BIOVIE INC worth?

BIOVIE INC (BIVI) has a market capitalization of 12.58M USD. This makes BIVI a Nano Cap stock.


How many employees does BIOVIE INC have?

BIOVIE INC (BIVI) currently has 14 employees.


What are the support and resistance levels for BIOVIE INC (BIVI) stock?

BIOVIE INC (BIVI) has a resistance level at 1.75. Check the full technical report for a detailed analysis of BIVI support and resistance levels.


Should I buy BIOVIE INC (BIVI) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BIOVIE INC (BIVI) stock pay dividends?

BIVI does not pay a dividend.


When does BIOVIE INC (BIVI) report earnings?

BIOVIE INC (BIVI) will report earnings on 2025-09-29, after the market close.


What is the Price/Earnings (PE) ratio of BIOVIE INC (BIVI)?

BIOVIE INC (BIVI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-21.14).


BIVI Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

BIVI Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to BIVI. The financial health of BIVI is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BIVI Financial Highlights

Over the last trailing twelve months BIVI reported a non-GAAP Earnings per Share(EPS) of -21.14. The EPS increased by 78.03% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -78.52%
ROE -88.75%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%92.46%
Sales Q2Q%N/A
EPS 1Y (TTM)78.03%
Revenue 1Y (TTM)N/A

BIVI Forecast & Estimates

7 analysts have analysed BIVI and the average price target is 56.1 USD. This implies a price increase of 3406.25% is expected in the next year compared to the current price of 1.6.


Analysts
Analysts82.86
Price Target56.1 (3406.25%)
EPS Next Y96.26%
Revenue Next YearN/A

BIVI Ownership

Ownership
Inst Owners5.58%
Ins Owners0.84%
Short Float %N/A
Short Ratio0.51